Table 3.
Univariate analysis of OS, NRM, Relapse
| Death | NRM | Relapse | ||||
|---|---|---|---|---|---|---|
|
|
||||||
| Variable | HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p |
|
| ||||||
| Age at HCT continuous | 1.06 (1.01–1.1) | 0.02 | 1.04 (0.98– 1.1) | 0.2 | 1.06 (0.99 – 1.1) | 0.1 |
|
| ||||||
| Age at HCT | 0.07 | 0.5 | 0.08 | |||
| Age<60 (n=54) | 1 | 1 | 1 | |||
| Age≥60 (n=46) | 1.8 (0.9–3.6) | 1.3 (0.6 – 2.9) | 2.5 (0.9 – 7.3) | |||
|
| ||||||
| Diagnosis | 0.2 | 0.3 | 0.7 | |||
| Primary MF (n=57) | 1 | 1 | 1 | |||
| Post ET MF (n=21) | 0.4 (0.2–1.2) | 0.4 (0.1– 1.4) | 0.6 (0.1 – 2.6) | |||
| Post PV MF (n=22) | 1.3 (0.6–2.7) | 0.9 (0.3 – 2.4) | 1.2 (0.4 – 4.0) | |||
|
| ||||||
| Cytogenetics | 0.6 | 0.6 | 0.06 | |||
| Normal (n=49) | 1 | 1 | 1 | |||
| Abnormal Std Risk (n=26) | 0.9 (0.4–2.0) | 0.6 (0.2 – 1.5) | 1.9 (0.5 – 6.8) | |||
| Abnormal High Risk (n=18) | 1.4 (0.6–3.2) | 0.7 (0.3 – 2.1) | 4.5 (1.4 – 14.4) | |||
|
| ||||||
| JAK2 mutation status | 0.2 | 0.5 | 0.6 | |||
| Mutated (n=62) | 1 | 1 | 1 | |||
| Wild type (n=37) | 0.6 (0.3–1.3) | 0.6 (0.3– 1.5) | 0.6 (0.2 – 1.8) | |||
|
| ||||||
| Response groups | 0.1 | 0.5 | 0.01 | |||
| Group-A (n=23) | 1 | 1 | 1 | |||
| Group-B (n=31) | 3.9 (1.1–13.7) | 2.8 (0.8 –10.4) | 1.3 (0.2 2– 7.2) | |||
| Group-C (n=15) | 4.4 (1.1–17.7) | 3.2 (0.8–12.7) | 0.9 (0.1– 10.2) | |||
| Group-D (n=18) | 4.3 (1.1–16.4) | 2.7 (0.7– 11.2) | 2.4 (0.4 – 13.4) | |||
| Group-E (n=13) | 6.4 (1.7–24.2) | 2.1 (0.4–10.1) | 7.5 (1.6 – 34.3) | |||
|
| ||||||
| Response: combined groups | 0.02 | 0.2 | 0.003 | |||
| Group-A (n=23) | 1 | 1 | 1 | |||
| Group-BCD (n=64) | 4.1 (1.2–13.5) | 2.9 (0.9–9.7) | 1.5 (0.3 – 6.8) | |||
| Group-E (n=13) | 6.4 (1.7–24.2) | 2.1 (0.4–10.1) | 7.4 (1.6 – 34.2) | |||
|
| ||||||
| DIPSS score prior to JAK# | 0.03 | 0.1 | 0.96 | |||
| Intermediate-1 (n=40) | 1 | 1 | 1 | |||
| Intermediate-2 (n=48) | 1.5 (0.7–3.3) | 1.2 (0.6 – 2.8) | 1.2 (0.4 – 3.4) | |||
| High-risk (n=6) | 5.0 (1.5–16.4) | 3.4 (0.7 –16.0) | 1.4 (0.2 – 12.6) | |||
|
| ||||||
| Palpable splenomegaly at HCT | 0.5 | 0.6 | 0.9 | |||
| Not palpable (n=14) | 1 | 1 | 1 | |||
| ≤10 cm BCM (n=39) | 0.8 (0.3–2.1) | 0.9 (0.3 – 2.9) | 0.7 (0.2 – 2.7) | |||
| > 10 cm BCM (n=33) | 1.01 (0.4–2.6) | 1.2 (0.4 – 3.9) | 0.6 (0. – 2.6) | |||
| Splenectomy (n=13) | 0.4 (0.1–1.5) | 0.2 (0.03 – 2.2) | 1.03 (0.2 – 4.7) | |||
|
| ||||||
| Circulating blast before JAK# | 0.2 | 0.5 | 0.0006 | |||
| <1% (n=32) | 1 | 1 | 1 | |||
| 1–9% (n=55) | 0.9 (0.4–2.0) | 1.2 (0.5 – 2.5) | 0.6 (0.2 – 1.8) | |||
| 10–19% (n=5) | 2.7 (0.8–8.6) | 0.0 (0.0 – 0.0) | 7.3 (2.2–24.0) | |||
|
| ||||||
| ECOG at HCT | 0.01 | 0.3 | 0.5 | |||
| 0 (n=20) | 1 | 1 | 1 | |||
| 1 (n=70) | 1.8 (0.6–5.1) | 2.0 (0.6 – 6.4) | 1.4 (0.3 – 6.8) | |||
| ≥2 (n=9) | 5.3 (1.6–18.2) | 3.8 (0.9 – 17.1) | 3.4 (0.6 – 20.6) | |||
|
| ||||||
| HCT-CI at HCT | 0.1 | 0.5 | 0.1 | |||
| 0 (n=30) | 1 | 1 | 1 | |||
| 1 or 2 (n=28) | 1.5 (0.5–4.3) | 1.7 (0.6 – 5.0) | 0.2 (0.02 – 1.6) | |||
| ≥3 (n=32) | 2.5 (1.0–6.2) | 1.9 (0.7 – 5.2) | 1.2 (0.4 – 3.5) | |||
|
| ||||||
| Donor | 0.004 | 0.005 | 0.01 | |||
| Matched Sibling (n=36) | 1 | 1 | 1 | |||
| Matched unrelated (n=50) | 1.9 (0.8–4.3) | 0.97 (0.4 – 2.4) | 10.4 (1.3 – 82.8) | |||
| Other (n=14) | 5.1 (1.9–13.4) | 4.0 (1.5–10.4) | 2.7 (0.2 – 45.4) | |||
|
| ||||||
| TCD | 0.8 | 0.4 | 0.09 | |||
| No (n=49) | 1 | 1 | 1 | |||
| Yes (n=51) | 0.9 (0.5–1.7) | 0.7 (0.3 – 1.5) | 2.6 (0.8 – 8.3) | |||
|
| ||||||
| Intensity of conditioning | 0.007 | 0.02 | 0.4 | |||
| Full intensity (n=44) | 1 | 1 | 1 | |||
| Reduced intensity (n=56) | 2.9 (1.3–6.1) | 2.8 (1.1 – 6.9) | 1.5 (0.6 – 4.6) | |||
HCT denotes, allogeneic hematopoietic cell transplantation; MF, myelofibrosis; ET, essential thrombocythemia; PV, polycythemia; DIPSS, Dynamic International Prognostic Scoring System; BCM, below left costal margin; JAK#, JAK1/2 inhibitor; ECOG, Eastern Cooperative Oncology Group Scoring; HCT-CI, hematopoietic cell transplantation comorbidity index; and TCD, T cell depletion.